In Silico Design and Evaluation of Novel Cell Targeting Melittin-Interleukin-24 Fusion Protein: A potential Drug Candidate Against Breast Cancer

• DOI: 10.17576/jsm-2023-5211-15
• Publication Date: 2024-01-17T05:41:45Z
• Authors: Hafiz Muhammad Re...; Hafiz Muzzammel R...; Nadeem Ahmed; Muhammad Imran Am...; Shakira Aslam; Hamid Bashir
• Keywords: Melittin; Ramachandran plot; MODELLER

Fusion proteins are designed to achieve new functionality or improved properties synergistically by incorporating multiple protein domains into one complex. The fusion of two genes translate a recombinant for cancer treatment can enhance the bioactivity drug and introduce novel candidate with wide range applications in pharmaceuticals biotechnology. Interleukin-24 (IL-24) is growth-suppressing apoptosis inducing cytokine while melittin natural honeybee derived cationic polypeptide having anti-tumor activity against breast cells. current study was aimed perform silico design analyses melittin-IL-24 cancer. amino acid sequences IL-24 peptide were used via rigid linker. Using online softwares we predicted secondary tertiary structures along physicochemical protein. validation quality confirmed Rampage ERRAT2. top ranked structure from I-TASSER showed 18.1KD molecular weight ProtParam, factor 94.152 ERRAT valid Ramachandran plot 88.5% residues favoured region. docking simulation studies performed using ClusPro Desmond software. quality, validity, interaction analysis stability depicted functional molecule. finding expression value 0.86 E. coli on SOLUPROT tool suggest that melittin- lead develop potent therapeutic